Provided by:
Penn Myeloproliferative Neoplasms
Weekly Case Conference
2015
Wednesday 10/7/2015
11:30-12PM
PCAM3 West Conference Room
Daria Babushok, MD PhD
“Novel Insights into MPN Pathogenesis: Osteogenic Potential of Mesenchymal Cells Contributes to
Primary Myelofibrosis”
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, and allied health professionals
in the medical specialties of hematology/oncology, pathology and laboratory medicine, hematopathology.
Educational Objectives
After completing this activity, participants should be able to:
 Improve competence in the use of the emerging diagnostic criteria and the standard-of-care for a wide variety
of myeloproliferative neoplasms

Improve knowledge of prognostic stratification of myeloproliferative neoplasms and risk-adapted treatment
strategies for a variety of myeloproliferative disorders

Recognize genetic changes seen in a variety of myeloproliferative neoplasms, as well as their prognostic
therapeutic implications
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of .50
AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Acknowledgement of Commercial Support*
NONE
For more information, please contact
Barbette Jackson
215-614-1847
Barbette.jackson@uphs.upenn.edu
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing
medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include
financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and
free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure
information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest
relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous
and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic,
Director of CME and the peer reviewer Zalman Agus, MD, have disclosed that they have no relevant financial
relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER AND SPEAKER NAMES
ELIZABETH HEXNER, MD, MSTR
VIKRAM PARALKAR, MD
PRESENTER NAME
ADAM BAGG
PETER KLEIN, MD, PHD
DARIA BABUSHOK, MD, PHD
DALE M. FRANK, MD
ROBERT ORLOWSKI, MD
The following individuals have reported the listed relevant financial relationships with commercial interests related to
the content of this educational activity.
PRESENTER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty,
intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding
diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position,
independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels,
board membership, and other activities from which remuneration is received or expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
PRESENTER NAME
PRODUCT
INVESTIGATIONAL AND/OR OFF-LABEL USE
ELIZABETH HEXNER, MD
ALL TREATMENTS FOR MPN ARE OFF LABEL WITH EXCEPTION OF ANAGRELIDE AND RUXOLITINIB
DARIA BABUSHOK, MD, PHD BECAUSE THIS IS A RAPIDLY EVOLVING AREA, OCCASIONALLY NEW DATA ON USE OF NEW AGENTS IN
MYELOPROLIFERATIVE DISORDERS MAY BE DISCUSSED, AS THESE COME UP.